Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Carcinoma in Situ

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44358   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    479 result(s) found for: Carcinoma in Situ. Displaying page 16 of 24.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    EudraCT Number: 2007-001152-39 Sponsor Protocol Number: SSG XX Start Date*: 2024-05-21
    Sponsor Name:Scandinavian Sarcoma Group
    Full Title: SSGXX A Scandinavian Sarcoma Group treatment protocol for adult patients with non-metastatic high-risk soft tissue sarcoma of the extremities and trunk wall
    Medical condition: SSG XX is a phase II trial for high-risk soft tissue sarcoma(STS) of the extremities and trunk wall. Prognostic markers are used to identify high-risk tumors. SSG XX will evaluate chemo-and radioth...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005081-17 Sponsor Protocol Number: ARV-471-BC-201 Start Date*: 2023-01-20
    Sponsor Name:Arvinas Estrogen Receptor, Inc. (Arvinas)
    Full Title: An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2– Breast Cancer in the Neoadjuvant Setting
    Medical condition: Post-menopausal women with ER+ HER2– breast cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002190-21 Sponsor Protocol Number: MAR-BAS-18-005 Start Date*: 2020-07-08
    Sponsor Name:Fondazione per la Medicina Personalizzata
    Full Title: The ROME trial from histology to target: the road to personalize target therapy and immunotherapy
    Medical condition: Patients with progressive disease (recurrent and/or metastatic) of breast cancer, metastatic gastro-intestinal tumors, non small cell lung cancer (NSCLC) or others. Patients should have completed a...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066275 Comedocarcinoma of breast LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10007351 Carcinoma gastrointestinal LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071533 Lung squamous cell carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004024-37 Sponsor Protocol Number: A6181109 Start Date*: 2007-07-05
    Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017
    Full Title: SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC
    Medical condition: Adjuvant treatment of subjects with “high risk” Renal Cell Carcinoma (RCC) following nephrectomy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) CZ (Completed) DE (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) SE (Completed) PL (Completed) SK (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003874-29 Sponsor Protocol Number: E-3810-II-02 Start Date*: 2014-01-20
    Sponsor Name:EOS S.p.A.
    Full Title: A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer
    Medical condition: FGFR1-amplified squamous non-small cell lung cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) DE (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005328-17 Sponsor Protocol Number: MO28048 Start Date*: 2012-04-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III prospective, two-cohort non-randomised, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in pati...
    Medical condition: HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) HU (Completed) PT (Completed) GB (Completed) NO (Completed) IT (Completed) GR (Completed) LT (Completed) PL (Completed) SI (Completed) SK (Completed) FI (Completed) BG (Completed) NL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000824-21 Sponsor Protocol Number: IJB-NERABRAIN-ODN-007 Start Date*: 2021-10-05
    Sponsor Name:Institut Jules Bordet
    Full Title: An open label phase II study to evaluate neratinib for treatment and prevention of subsequent CNS event(s) in patients with brain metastasis of advanced HER2 positive breast cancer
    Medical condition: HER2 positive breast cancer patients with brain metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002437-21 Sponsor Protocol Number: GEICAM/2014-12 Start Date*: 2015-11-09
    Sponsor Name:GEICAM (Spanish Breast Cancer Research Group Foundation)
    Full Title: A randomized, double-blind, parallel-group, multicentre, phase II study to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo and fulvestrant (FaslodexTM) 500mg in...
    Medical condition: Postmenopausal women presenting with HR-positive/HER2-negative metastatic breast cancer who have received at least 5 years of endocrine therapy in the adjuvant setting as treatment for early diseas...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004472-30 Sponsor Protocol Number: MITO23 Start Date*: 2015-12-02
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Randomized phase III trial on Trabectedin (ET-743) vs clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
    Medical condition: recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or BRCAness phenotype patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006888 Ca ovary LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003112-31 Sponsor Protocol Number: LP0041-63 Start Date*: 2013-07-13
    Sponsor Name:LEO Pharma A/S
    Full Title: Risk of Squamous Cell Carcinoma on Skin Areas Treated with Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
    Medical condition: Actinic keratosis on the face and scalp
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000654-23 Sponsor Protocol Number: EORTC 18032 Start Date*: 2004-12-09
    Sponsor Name:EORTC
    Full Title: Extended schedule, escalated dose Temozolomide versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group
    Medical condition: Stage IV Metastatic Melanoma:
    Disease: Version SOC Term Classification Code Term Level
    7.0 10027480 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006363-24 Sponsor Protocol Number: TTD-06-04 Start Date*: 2007-04-20
    Sponsor Name:Grupo de Tratamiento de los Tumores Digestivos (TTD)
    Full Title: An Phase 2 Clinical Trial of Panitumumab in Conbination vith Irinotecan chemotherapy as 2nd line Therapy in subjects with Metastatic Colorectal Cancer. Ensayo Clínico fase II de Panitumumab combin...
    Medical condition: Cáncer colorectal metastásico.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-002760-16 Sponsor Protocol Number: 04/QO603/42 HEXVIX Start Date*: 2005-01-12
    Sponsor Name:Guy's and St Thomas' NHS Foundation Trust
    Full Title: A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bl...
    Medical condition: Superficial Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004505-29 Sponsor Protocol Number: 2676 Start Date*: 2008-05-15
    Sponsor Name:Royal Marsden NHS Trust
    Full Title: Phase II clinical trial of capecitabine and oxaliplatin plus bevacizumab as neoadjuvant treatment for patients with previously untreated unresectable liver-only metastases from colorectal cancer
    Medical condition: Metastatic colorectal adenocarcinoma with metastases involving the liver only
    Disease: Version SOC Term Classification Code Term Level
    8.1 10010035 Colorectal cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-010975-26 Sponsor Protocol Number: ACROSS-08-01 Start Date*: 2009-07-16
    Sponsor Name:Associació Catalana per a la Recerca Oncológica i les seves implicacions Sanitáries i Socials
    Full Title: Estudio clínico abierto de fase II de panitumumab en combinación con quimioterapia FOLFIRI como tratamiento de segunda línea en sujetos con cáncer colorrectal metastásico que expresa KRAS no mutado...
    Medical condition: Cáncer colorrectal metastásico que expresa KRAS no mutado
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001036-22 Sponsor Protocol Number: SOLTI-1114 Start Date*: 2013-10-15
    Sponsor Name:SOLTI
    Full Title: PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer
    Medical condition: Untreated invasive breast carcinoma eligible for primary definitive surgery (Stage I-IIIA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001181-36 Sponsor Protocol Number: SOLTI-2103 Start Date*: 2022-11-21
    Sponsor Name:SOLTI
    Full Title: A phase 2 trial of neoadjuVAnt muLti-agENt chemotherapy or patritumab deruxtecan (HER3-DXd; HER3-DXd) with or without endocrINE therapy for high-risk HR+/HER2- breast cancer – VALENTINE trial
    Medical condition: treatment naïve patients with HR+/HER2-negative high-risk early breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000432-10 Sponsor Protocol Number: 26866138MMY2084 Start Date*: 2013-05-23
    Sponsor Name:DUTCH BELGIAN COOPERATIVE GROUP FOR HEMATOLOGY ONCOLOGY - HOVON
    Full Title: A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PAT...
    Medical condition: Patients with Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001503-20 Sponsor Protocol Number: MedOPP150(ATRACTIB) Start Date*: 2021-07-30
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGAT...
    Medical condition: Advanced or metastatic triple-negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004651-23 Sponsor Protocol Number: IJB-SYNERGY-012017 Start Date*: 2018-10-16
    Sponsor Name:Institut Jules Bordet
    Full Title: A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative ...
    Medical condition: Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006198 Breast cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 12  13  14  15  16  17  18  19  20  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Sep 04 21:47:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA